Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exercise testing in heart failure. A critical review

K Swedberg1

  • 1Department of Medicine, Göteborg University, Ostra Hospital, Sweden.

Drugs
|January 1, 1994
PubMed
Summary

Exercise testing in chronic heart failure (CHF) is common but doesn't predict survival benefits from medications. Neuroendocrine activation better reflects mortality changes, offering a more reliable measure for drug efficacy in CHF patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme.

Blood pressure·2017
Same author

Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis.

QJM : monthly journal of the Association of Physicians·2015
Same author

Trends in mortality after first hospitalization with atrial fibrillation diagnosis in Sweden 1987 to 2006.

International journal of cardiology·2014
Same author

Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.

International journal of cardiology·2013
Same author

The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data.

International journal of obesity (2005)·2013
Same author

Effect of nesiritide in patients with acute decompensated heart failure.

The New England journal of medicine·2011

Area of Science:

  • Cardiology
  • Exercise Physiology
  • Pharmacology

Background:

  • Exercise intolerance is a hallmark of chronic congestive heart failure (CHF).
  • Exercise testing is crucial for assessing CHF severity and drug efficacy in clinical trials.
  • Maximal exercise capacity is commonly measured via exercise duration, maximal oxygen consumption, or anaerobic threshold.

Purpose of the Study:

  • To evaluate the utility of exercise testing in assessing drug therapy effects in CHF patients.
  • To identify more reliable markers for evaluating pharmacological interventions in CHF.

Main Methods:

  • Review of exercise testing protocols used in CHF assessment.
  • Analysis of correlations between exercise capacity changes and mortality rates in clinical trials.
  • Comparison of exercise testing with neuroendocrine markers for predicting drug efficacy.

Main Results:

  • Baseline exercise testing quantifies CHF severity and prognosis but has limited value for assessing drug therapy effects.
  • Changes in exercise capacity due to drug interventions do not consistently correlate with mortality rate changes.
  • Angiotensin-converting enzyme (ACE) inhibitors show modest effects on exercise capacity but improve survival.
  • Neuroendocrine activation appears to correlate more closely with mortality rates and survival changes from pharmacological interventions.

Conclusions:

  • Exercise testing is insufficient for evaluating the impact of drug therapies on mortality in CHF.
  • Neuroendocrine activation is a more sensitive indicator of treatment response and survival benefits in CHF patients.
  • Future research should focus on neuroendocrine markers for assessing pharmacological interventions in CHF.

Related Experiment Videos